Abstract
Signs of immediate and delayed secondary toxicity have been examined in various systems of polychemical therapy undergone by 39 patients suffering from 'small cell lung cancer' (SCLC) and 72 with 'non-small cell lung cancer' (NSCLC). As to the therapeutic response, NSCLC cases are better treated with low-toxicity, well tolerated drugs. On the other hand, in SCLC cases which respond well to therapy, secondary toxicity is acceptable, given the patients' increased chances of survival.
| Original language | Italian |
|---|---|
| Pages (from-to) | 215-220 |
| Number of pages | 6 |
| Journal | Minerva Pneumologica |
| Volume | 20 |
| Issue number | 4 |
| Publication status | Published - 1981 |
Fingerprint
ASJC Scopus subject areas
- Pulmonary and Respiratory Medicine
Cite this
TOSSICITA SECONDARIA IMMEDIATA E RITARDATA DI VARI SCHEMI DI POLICHEMIOTERAPIA DEL CARCINOMA DEL POLMONE ALLO STADIO III INOPERABILE. / De Marinis, F.; Maccone, C.; Carminati, F.; Pallotta, F.
In: Minerva Pneumologica, Vol. 20, No. 4, 1981, p. 215-220.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - TOSSICITA SECONDARIA IMMEDIATA E RITARDATA DI VARI SCHEMI DI POLICHEMIOTERAPIA DEL CARCINOMA DEL POLMONE ALLO STADIO III INOPERABILE
AU - De Marinis, F.
AU - Maccone, C.
AU - Carminati, F.
AU - Pallotta, F.
PY - 1981
Y1 - 1981
N2 - Signs of immediate and delayed secondary toxicity have been examined in various systems of polychemical therapy undergone by 39 patients suffering from 'small cell lung cancer' (SCLC) and 72 with 'non-small cell lung cancer' (NSCLC). As to the therapeutic response, NSCLC cases are better treated with low-toxicity, well tolerated drugs. On the other hand, in SCLC cases which respond well to therapy, secondary toxicity is acceptable, given the patients' increased chances of survival.
AB - Signs of immediate and delayed secondary toxicity have been examined in various systems of polychemical therapy undergone by 39 patients suffering from 'small cell lung cancer' (SCLC) and 72 with 'non-small cell lung cancer' (NSCLC). As to the therapeutic response, NSCLC cases are better treated with low-toxicity, well tolerated drugs. On the other hand, in SCLC cases which respond well to therapy, secondary toxicity is acceptable, given the patients' increased chances of survival.
UR - http://www.scopus.com/inward/record.url?scp=0019842120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0019842120&partnerID=8YFLogxK
M3 - Articolo
AN - SCOPUS:0019842120
VL - 20
SP - 215
EP - 220
JO - Minerva Pneumologica
JF - Minerva Pneumologica
SN - 0026-4954
IS - 4
ER -